Abstract
Background
It had been assumed that suppressing the undamaged contralesional motor cortex by repetitive low-frequency transcranial magnetic stimulation (rTMS) or increasing the excitability of the damaged hemisphere cortex by high-frequency rTMS will promote function recovery after stroke.
Objectives
To assess the efficacy and safety of rTMS for improving function in people with stroke.
Search methods
We searched the Cochrane Stroke Group Trials Register (April 2012), the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2012, Issue 4), the Chinese Stroke Trials Register (April 2012), MEDLINE (1950 to May 2012), EMBASE (1980 to May 2012), Science Citation Index (1981 to April 2012), Conference Proceedings Citation Index-Science (1990 to April 2012), CINAHL (1982 to May 2012), AMED (1985 to May 2012), PEDro (April 2012), REHABDATA (April 2012) and CIRRIE Database of International Rehabilitation Research (April 2012). In addition, we searched five Chinese databases, ongoing trials registers and relevant reference lists.
Selection criteria
We included randomised controlled trials comparing rTMS therapy with sham therapy or no therapy. We excluded trials that reported only laboratory parameters.
Data collection and analysis
Two review authors independently selected trials, assessed trial quality and extracted the data. We resolved disagreements by discussion.
Main results
We included 19 trials involving a total of 588 participants in this review. Two heterogenous trials with a total of 183 participants showed that rTMS treatment was not associated with a significant increase in the Barthel Index score (mean difference (MD) 15.92, 95% CI -2.11 to 33.95). Four trials with a total of 73 participants were not found to have a statistically significant effect on motor function (standardised mean difference (SMD) 0.51, 95% CI -0.99 to 2.01). Subgroup analyses of different stimulation frequencies or duration of illness also showed no significant difference. Few mild adverse events were observed in the rTMS groups, with the most common events being transient or mild headaches (2.4%, 8/327) and local discomfort at the site of the stimulation.
Authors’ conclusions
Current evidence does not support the routine use of rTMS for the treatment of stroke. Further trials with larger sample sizes are needed to determine a suitable rTMS protocol and the long-term functional outcome.
Plain language summary
Magnetic brain stimulation for improving people’s functional ability after stroke
The human brain has two hemispheres. For people who have had a stroke, activity in the affected hemisphere is disrupted not only by the damage caused by the stroke itself, but also by the reaction of the unaffected hemisphere, which tries to limit the damage caused by the stroke. This limiting effect, while beneficial in the initial stage after stroke, may subsequently become detrimental as it interferes with the brain’s capacity to recover functional ability. Repetitive transcranial magnetic stimulation (rTMS) is a method of non-invasive brain stimulation that can help the affected hemisphere to repair the damage of the stroke, while decreasing the limiting effect on recovery caused by undamaged hemisphere. rTMS has been investigated in the treatment of many conditions, including depression, tinnitus and movement disorders. The aim of this review was to assess randomised controlled trials of rTMS on functional recovery in patients with stroke. We included 19 trials with a total of 588 patients in the review. We found that rTMS treatment was not associated with improved activities of daily living nor had a statistically significant effect on motor function. The current evidence is not yet sufficient to support the routine use of rTMS for the treatment of stroke.
